No discrete events today — but a coordinated same-day refresh of 15 Phase 2/3 trials across Amgen's MariTide, Lilly's eloralintide/orforglipron/retatrutide, and Novo's NNC0487-0111 programs signals broad obesity-franchise recruitment expansion. — 15 trials with material updates.

Competitive Intelligence · Obesity & T2D

Thursday, May 14, 2026

No discrete events today — but a coordinated same-day refresh of 15 Phase 2/3 trials across Amgen's MariTide, Lilly's eloralintide/orforglipron/retatrutide, and Novo's NNC0487-0111 programs signals broad obesity-franchise recruitment expansion.

Key Signals · 15 trials updated

  • Amgen — entire maridebart cafraglutide (MariTide) Phase 3 program refreshed same-day: CVOT (NCT07037433, 12,800 pts, now 766 sites across 35 countries), HFpEF (NCT07037459, 5,056 pts), and both OSA trials (NCT07226765, NCT07225686)
  • Eli Lilly — eloralintide (LY3841136) Phase 3 program refreshed across all four indications at once: obesity ±T2DM (NCT07321886, NCT07282600), OA knee pain (NCT07353931), OSA (NCT07369011)
  • Eli Lilly — orforglipron Phase 3 comorbidity trials refreshed (knee OA NCT07153471, stress urinary incontinence NCT07202884), alongside retatrutide obesity P3 (NCT07357415), the LY900038 master protocol (NCT06143956), and the macupatide+eloralintide combo P2 (NCT07215559)
  • Novo Nordisk — NNC0487-0111 Phase 3 in obesity + knee OA refreshed (NCT07481630)
  • No status transitions, results postings, or new trial registrations in the last 24h — the signal is coordinated Phase 3 site/recruitment expansion across all three obesity leaders, not discrete events

What posted in the last 24 hours

15 in-scope Phase 2/3 trials from named sponsors had updates post on 2026-05-14 (all submitted 2026-05-13). None were new registrations, status transitions, or results postings — every one is an update to an already-recruiting study. With that many major-program trials refreshing on a single submit date, the most likely driver is geographic site additions / recruitment-status updates, a material signal under the current criteria. Treat today as program-momentum intelligence rather than a discrete-event day.

Amgen — MariTide (maridebart cafraglutide) Phase 3 program

All four Phase 3 trials refreshed same-day:

  • NCT07037433 — CVOT in ASCVD + overweight/obesity. 12,800 pts, primary completion 2028-06-30, final completion 2030-09-29. Verified detail: now 766 sites across 35 countries (incl. US, EU4, Japan, China) — a very large, actively expanding global footprint.
  • NCT07037459 — HFpEF/HFmrEF + obesity, 5,056 pts.
  • NCT07226765 — OSA, not on PAP therapy, 250 pts.
  • NCT07225686 — OSA, on PAP therapy, 250 pts.
  • Signal: Amgen pushing its long-acting anti-obesity antibody across CV outcomes and comorbidity indications in parallel. The CVOT scale (12,800 pts / 766 sites) is the headline competitive datapoint.

Eli Lilly — eloralintide (LY3841136) Phase 3 program

All four registered Phase 3 indications refreshed same-day:

  • NCT07321886 — obesity/overweight without T2DM, 1,980 pts.
  • NCT07282600 — obesity/overweight with T2DM, 1,035 pts.
  • NCT07353931 — OA knee pain + obesity/overweight, 900 pts.
  • NCT07369011 — OSA + obesity/overweight, 800 pts.
  • NCT07392190 — persistent obesity on a weekly incretin, 900 pts.
  • Signal: Lilly is running eloralintide as a full next-wave obesity franchise with comorbidity-specific pivotal trials; combined Phase 3 enrollment ~5,600+. Coordinated refresh suggests synchronized recruitment ramp.

Eli Lilly — orforglipron, retatrutide, and platform protocols

  • NCT07153471 — orforglipron in obesity/overweight + knee OA, P3, 800 pts.
  • NCT07202884 — orforglipron in female stress urinary incontinence + obesity/overweight, P3, 1,000 pts.
  • NCT07357415 — retatrutide (triple agonist) in obesity without T2DM, P3, 600 pts.
  • NCT06143956 — LY900038 master protocol (P2 platform; ISAs include LY3549492, eloralintide, tirzepatide, macupatide), 1,481 pts.
  • NCT07215559 — macupatide (LY3532226) + eloralintide combination, P2, obesity/overweight + T2DM, 200 pts.
  • Signal: Lilly refreshed trials spanning four distinct obesity mechanisms on the same day — orforglipron (oral GLP-1), retatrutide (triple agonist), eloralintide/macupatide (amylin-class), and the LY900038 platform.

Novo Nordisk — NNC0487-0111

  • NCT07481630 — NNC0487-0111 in obesity + knee OA, P3, 400 pts.
  • Signal: Novo's next-gen molecule continuing its pivotal program; today's refresh is the only Novo in-scope update in the 24h window.

Read for the day

Quiet on discrete events (no completions, terminations, or readouts), but the synchronized refresh of Amgen's, Lilly's, and Novo's flagship obesity Phase 3 programs on one submit date is itself the intelligence: all three leaders appear to be in a coordinated recruitment-expansion push. Worth confirming via site-count diffs on subsequent runs to distinguish genuine geographic expansion from routine administrative refreshes.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-05-15T02:02:24.692Z